Pembrolizumab in Neoplasms or Lymphomas

NCT03316573 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Lymphoma
Histiocytic Sarcoma
Follicular Dendritic Cell Sarcoma
Interdigitating Dendritic Cell Sarcoma

Interventions

DRUG: Pembrolizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]